Claudine E. Bruck
Founder of Prolifagen LLC, Claudine E. Bruck presently holds the position of Chairman for Prolifagen LLC and Chief Scientific Officer of SapVax LLC. Dr. Bruck is also on the board of Annovis Bio, Inc.
She previously was Head-Cancer Vaccine Program at GlaxoSmithKline LLC, Course Director at the University of Pennsylvania and Assistant Professor at Tufts University School of Medicine.
Claudine E. Bruck received a doctorate from Vrije Universiteit Brussel and a graduate degree from Harvard Medical School.
Transactions
Date
Transaction
Value
| 10/11/2021 | 181 | Acquisition at $27.66 per share. | 5,006 |
| 01/31/2020 | 1,117 | Derivative/Non-derivative trans. at $4.8 per share. | 5,361 |
| 01/31/2020 | 3,969 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 01/31/2020 | 800 | Acquisition at $6 per share. | 4,800 |
